The Key Players in Global Heparin Market 2015-2019

Tuesday 16 June 2015, Amsterdam

Market Research Report Press Release

The report recognizes the following companies as the key players in the global heparin market: Aspen, Leo Pharma, Pfizer and Sanofi-Aventis

Other Prominent Vendors in the market are: Alchemia, Archimedes Pharma, Celgene, Dr. Reddy's, Eisai, Laboratorios Rovi Pharmaceuticals, Lee's Pharmaceutical, Menarini Group, Mylan, Sagent Pharmaceuticals, Fresenius Kabi, GlaxoSmithKline, Hospira, Sigma Tau and UCB

Commenting on the report, an analyst said: “The anti-inflammatory activity of heparin is a recent discovery. Heparin exhibits this trait through the neutralization of cationic mediators, inhibition of adhesion molecules, and the inhibition of heparanase, all of which are involved in leukocyte recruitment into tissues. Further studies are being conducted to exploit the use of heparin as an anti-inflammatory agent.”

According to the report, the growing prevalence of diseases is one of the key drivers of the market. Diseases such as coronary heart disease, kidney disorders, stroke, and inflammatory conditions are a result of blood clots, leading to a rise in the demand for heparin drugs.

Further, the report states that the patent expiry of top-selling drugs is a major challenge to vendors in the market, leading to the entry of generic drugs in the market and, consequently, a reduction in the price of branded drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Global Heparin Market 2015-2019

Global Heparin Market 2015-2019

Publish date : June 2015
Report code : ASDR-203989
Pages : 80

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News